

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10581000	
	Filing Date		2007-05-10	
	First Named Inventor	Rudiger Woscholski		
	Art Unit	4014 1621		
	Examiner Name	Porfirio Nazario-Gonzalez		
Attorney Docket Number		4033.3003 US		

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
/P.N./	1	20030055106	A1	2003-03-20	Faure, Robert et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
/P.N./	1	00/57860	WO	A2	2000-10-05	Centre for Translational Research in Cancer, Can.		<input type="checkbox"/>
/P.N./	2	2004/018655	WO	A2	2004-03-04	Neuronova AB, Swed.		<input type="checkbox"/>
/P.N./	3	2 396 106	GB	A	2004-06-16	Johnson & Johnson Medical Limited, UK		<input type="checkbox"/>

Receipt date: 06/19/2008

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10581000
Filing Date	2007-05-10
First Named Inventor	Rudiger Woscholski
Art Unit	<del>4644</del> 1621
Examiner Name	Porfirio Nazario-Gonzalez
Attorney Docket Number	4033.3003 US

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
/P.N./	1	SCHMID, Annette C., et al., "Bisperoxovanadium compounds are potent PTEN inhibitors," FEBS Letters, 566: 35-38 (2004).	<input type="checkbox"/>
/P.N./	2	NOLTE, Lorraine A., et al., "A peroxovanadium compound stimulates muscle glucose transport as powerfully as insulin and contractions combined," Diabetes, 52(8): 1918-1925 (2003).	<input type="checkbox"/>
/P.N./	3	BAND, Christian J., et al., "Early signaling events triggered by peroxovanadium [bpV(phen)] are insulin receptor kinase (IRK)-dependent: specificity of inhibition of IRK-associated protein tyrosine phosphatase(s) by bpV(phen)," Molecular Endocrinology, 11(13): 1889-1910 (1997).	<input type="checkbox"/>
/P.N./	4	BAND, Christian J. and POSNER, Barry I., "Phosphatidylinositol 3'-Kinase and p70s6k are Required for Insulin but not Bisperoxovanadium 1, 10-phenanthroline (bpv(phen)) Inhibition of Insulin-like Growth Factor Binding Protein Gene Expression," J. Biological Chemistry, 272(1): 138-145 (1997).	<input type="checkbox"/>
/P.N./	5	BARAT, Corrine and TREMBLAY, Michael J., "Treatment of Human T Cells with Bisperoxovanadium Phosphotyrosyl Phosphatase Inhibitors Leads to Activation of Cyclooxygenase-2 Gene," J. Biological Chemistry, 278(9): 6992-7000 (2002).	<input type="checkbox"/>
/P.N./	6	SASAGAWA, Takahiro, et al., "Bis(6-ethylpicolinate)oxovanadium(IV) Complex with Normoglycemic Activity in KK-Ay Mice," J. Inorganic Biochemistry, 88(1): 108-112 (2002).	<input type="checkbox"/>
/P.N./	7	KOZLOV, Alexander, et al., "Zeolite-encapsulated vanadium picolinate peroxo complexes active for catalytic hydrocarbon oxidations," J. Molecular Catalysis A: Chemical, 137: 223-237 (1999).	<input type="checkbox"/>
/P.N./	8	POSNER, B.I., et al., "Peroxovanadium Compounds. A New Class of Potent Phosphotyrosine Phosphatase Inhibitors Which are Insulin Mimetics, J. Biol. Chem., 269 (6): 4596-4604 (1994).	<input type="checkbox"/>
/P.N./	9	CUNCIC, C., et al., "Vanadate Inhibition of Protein Tyrosine Phosphatases in Jurkat Cells: Modulation by Redox State," J. Biol. Inorg. Chem., 4: 354-359 (1999).	<input type="checkbox"/>

Receipt date: 06/19/2008

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Not for submission under 37 CFR 1.99)

Application Number	10581000
Filing Date	2007-05-10
First Named Inventor	Rudiger Woscholski
Art Unit	<del>4044</del> 1621
Examiner Name	Porfirio Nazario-Gonzalez
Attorney Docket Number	4033.3003 US

/P.N./	10	HUYER, G., et al., "Mechanism of Inhibition of Protein-Tyrosine Phosphatases by Vanadate and Pervanadate," J. Biol. Chem., 272(2): 843-851 (1997).	<input type="checkbox"/>
/P.N./	11	RUMORA, L., et al., "Differential Regulation of JNK Activation and MKP-1 Expression by Peroxovanadium Complexes," Neurochem. Int., 38: 341-347 (2001).	<input type="checkbox"/>
/P.N./	12	SHISHEVA, A. and SHECHTER, Y., et al., "Mechanism of Pervanadate Stimulation and Potentiation of Insulin-Activated Glucose Transport in Rat Adipocytes: Dissociation from Vanadate Effect," Endocrinology, 133(4): 1562-1568 (1993).	<input type="checkbox"/>
/P.N./	13	WILDEN, P.A. and BROADWAY, D., "Combination of Insulinomimetic Agents H <sub>2</sub> O <sub>2</sub> and Vanadate Enhances Insulin Receptor Mediated Tyrosine Phosphorylation of IRS-1 Leading to IRS-1 Association with the Phosphatidylinositol 3-kinase," J. Cell Biochem., 58: 279-291 (1995).	<input type="checkbox"/>
/P.N./	14	SHECHTER, Y., "Insulin-Mimetic Effects of Vanadate. Possible Implications for Future Treatment of Diabetes," Diabetes, 39: 1-5 (1990).	<input type="checkbox"/>
/P.N./	15	STEPHENS, L.R., et al., "Agonist-Stimulated Synthesis of Phosphatidylinositol(3,4,5)-Trisphosphate: A New Intracellular Signalling System?" Biochim. et Biophys. Acta, 1179: 27-75 (1993).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Porfirio Nazario Gonzalez/	Date Considered	11/20/2009
--------------------	-----------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.